AN2 Therapeutics (ANTX)
AN2 Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
2.9M
Short interest
settlement 2026-10-15
7.4
Days to cover
-2.1 days vs prior
42.0%
Short share of volume
2026-11-02
3,427
Fails to deliver
settlement 2026-09-22
Wed 11 Nov
Next earnings
estimated date
-$307K
Insider flow, 90 days
1 buys, 9 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ANTX is 2,887,692 shares, up 490,385 shares over the last month. Over the last 48 readings it ranged from 14,430 shares (31 July 2025) to 2,887,692 shares (15 October 2026). The latest reading sits at the top of that range. At the reported average volume of 391K shares a day that is 7.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/antx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,887,692 | +15.9% | 390,811 | 7.39 |
| 2026-09-30 | 2,491,971 | +4.0% | 261,160 | 9.54 |
| 2026-09-15 | 2,397,307 | -4.4% | 203,314 | 11.79 |
| 2026-08-31 | 2,507,571 | +12.8% | 217,471 | 11.53 |
| 2026-08-14 | 2,223,166 | -6.5% | 219,629 | 10.12 |
| 2026-07-31 | 2,377,829 | -2.4% | 161,159 | 14.75 |
| 2026-07-15 | 2,435,644 | +26.6% | 246,030 | 9.90 |
| 2026-06-30 | 1,923,757 | +47.3% | 670,298 | 2.87 |
| 2026-06-15 | 1,305,874 | +8.2% | 188,877 | 6.91 |
| 2026-05-29 | 1,207,503 | +44.4% | 223,905 | 5.39 |
| 2026-05-15 | 836,372 | -4.9% | 240,708 | 3.47 |
| 2026-04-30 | 879,488 | +38.7% | 265,395 | 3.31 |
| 2026-04-15 | 633,935 | +12.3% | 416,717 | 1.52 |
| 2026-03-31 | 564,275 | -20.7% | 404,664 | 1.39 |
| 2026-03-13 | 711,585 | +1122.5% | 7,411,726 | 1.00 |
| 2026-02-27 | 58,207 | +9.5% | 85,374 | 1.00 |
| 2026-02-13 | 53,144 | +1.1% | 57,059 | 1.00 |
| 2026-01-30 | 52,574 | +5.2% | 73,228 | 1.00 |
| 2026-01-15 | 50,000 | +11.4% | 188,023 | 1.00 |
| 2025-12-31 | 44,898 | +8.6% | 44,696 | 1.00 |
| 2025-12-15 | 41,353 | +10.0% | 71,635 | 1.00 |
| 2025-11-28 | 37,586 | -20.9% | 44,908 | 1.00 |
| 2025-11-14 | 47,530 | +24.6% | 103,718 | 1.00 |
| 2025-10-31 | 38,130 | -6.3% | 80,816 | 1.00 |
| 2025-10-15 | 40,679 | -40.1% | 46,215 | 1.00 |
| 2025-09-30 | 67,864 | +15.5% | 79,866 | 1.00 |
| 2025-09-15 | 58,758 | +92.9% | 113,061 | 1.00 |
| 2025-08-29 | 30,463 | +100.2% | 104,637 | 1.00 |
| 2025-08-15 | 15,217 | +5.5% | 60,336 | 1.00 |
| 2025-07-31 | 14,430 | -56.5% | 79,066 | 1.00 |
| 2025-07-15 | 33,212 | -3.7% | 69,719 | 1.00 |
| 2025-06-30 | 34,475 | -34.4% | 446,949 | 1.00 |
| 2025-06-13 | 52,543 | +58.4% | 159,422 | 1.00 |
| 2025-05-30 | 33,176 | -21.8% | 377,595 | 1.00 |
| 2025-05-15 | 42,423 | +17.7% | 233,212 | 1.00 |
| 2025-04-30 | 36,054 | -56.2% | 32,367 | 1.11 |
| 2025-04-15 | 82,335 | +34.6% | 70,887 | 1.16 |
| 2025-03-31 | 61,160 | -14.1% | 80,512 | 1.00 |
| 2025-03-14 | 71,203 | -36.5% | 159,678 | 1.00 |
| 2025-02-28 | 112,040 | +42.6% | 157,667 | 1.00 |
| 2025-02-14 | 78,578 | +33.5% | 156,231 | 1.00 |
| 2025-01-31 | 58,838 | -25.1% | 115,411 | 1.00 |
| 2025-01-15 | 78,586 | -12.7% | 125,357 | 1.00 |
| 2024-12-31 | 90,026 | +21.5% | 184,833 | 1.00 |
| 2024-12-13 | 74,084 | +3.7% | 285,614 | 1.00 |
| 2024-11-29 | 71,424 | -81.2% | 1,774,853 | 1.00 |
| 2024-11-15 | 379,597 | +184.2% | 566,814 | 1.00 |
| 2024-10-31 | 133,574 | -4.0% | 216,444 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ANTX volume is 42.0%, down 33.5 points over the last five sessions. Over the last 30 readings it ranged from 30.7% (27 October 2026) to 88.3% (20 October 2026). The latest reading is 16.0 points below the 30-session average of 58.0%, on 111K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 47K | 111K | 42.0% | 0 |
| 2026-10-30 | 53K | 120K | 43.8% | 0 |
| 2026-10-29 | 153K | 315K | 48.5% | 0 |
| 2026-10-28 | 73K | 214K | 34.3% | 100 |
| 2026-10-27 | 17K | 54K | 30.7% | 0 |
| 2026-10-26 | 50K | 66K | 75.5% | 0 |
| 2026-10-23 | 27K | 42K | 63.5% | 0 |
| 2026-10-22 | 18K | 32K | 56.1% | 0 |
| 2026-10-21 | 52K | 60K | 87.5% | 0 |
| 2026-10-20 | 37K | 42K | 88.3% | 0 |
| 2026-10-19 | 111K | 134K | 82.8% | 0 |
| 2026-10-16 | 74K | 110K | 67.4% | 0 |
| 2026-10-15 | 57K | 132K | 43.2% | 0 |
| 2026-10-14 | 76K | 114K | 67.1% | 559 |
| 2026-10-13 | 64K | 149K | 42.8% | 86 |
| 2026-10-12 | 65K | 102K | 63.6% | 0 |
| 2026-10-09 | 93K | 251K | 36.9% | 0 |
| 2026-10-08 | 47K | 99K | 47.5% | 0 |
| 2026-10-07 | 54K | 154K | 35.2% | 541 |
| 2026-10-06 | 51K | 78K | 65.8% | 1,647 |
| 2026-10-05 | 70K | 121K | 57.7% | 0 |
| 2026-10-02 | 48K | 118K | 40.7% | 0 |
| 2026-10-01 | 76K | 163K | 46.9% | 0 |
| 2026-09-30 | 28K | 47K | 58.3% | 0 |
| 2026-09-29 | 21K | 31K | 68.9% | 0 |
| 2026-09-28 | 65K | 138K | 47.0% | 0 |
| 2026-09-25 | 26K | 42K | 63.1% | 0 |
| 2026-09-24 | 70K | 86K | 81.5% | 0 |
| 2026-09-23 | 118K | 145K | 81.3% | 0 |
| 2026-09-22 | 38K | 53K | 70.8% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 22 September 2026, the fails-to-deliver balance in ANTX is 3,427 shares, down 5,163 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (7 August 2026) to 507,844 shares (30 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-22 | 3,427 | $4.96 | $17K |
| 2026-09-21 | 8,590 | $5.05 | $43K |
| 2026-09-04 | 3,018 | $5.95 | $18K |
| 2026-08-21 | 35,402 | $5.79 | $205K |
| 2026-08-20 | 35,402 | $5.96 | $211K |
| 2026-08-19 | 35,402 | $5.97 | $211K |
| 2026-08-18 | 35,402 | $5.73 | $203K |
| 2026-08-07 | 2 | $6.08 | $12 |
| 2026-07-22 | 2,641 | $5.00 | $13K |
| 2026-07-21 | 8,729 | $4.80 | $42K |
| 2026-07-20 | 3,841 | $4.68 | $18K |
| 2026-07-17 | 15,702 | $4.67 | $73K |
| 2026-07-16 | 268,675 | $4.67 | $1.3M |
| 2026-07-15 | 272,075 | $4.76 | $1.3M |
| 2026-07-14 | 268,682 | $4.55 | $1.2M |
| 2026-07-13 | 254,786 | $4.50 | $1.1M |
| 2026-07-10 | 6 | $4.63 | $28 |
| 2026-07-09 | 6 | $4.41 | $26 |
| 2026-07-08 | 34,232 | $4.30 | $147K |
| 2026-07-07 | 32,204 | $4.41 | $142K |
| 2026-07-06 | 40,064 | $4.42 | $177K |
| 2026-07-02 | 353,454 | $4.70 | $1.7M |
| 2026-07-01 | 495,404 | $4.84 | $2.4M |
| 2026-06-30 | 507,844 | $5.03 | $2.6M |
| 2026-06-29 | 495,475 | $5.20 | $2.6M |
| 2026-06-26 | 336,039 | $5.14 | $1.7M |
| 2026-06-25 | 310,027 | $5.20 | $1.6M |
| 2026-06-24 | 306,250 | $4.98 | $1.5M |
| 2026-06-23 | 149,280 | $5.40 | $806K |
| 2026-06-22 | 164 | $5.00 | $820 |
Insider trades
SEC Form 4, newest first. JSONOver the last 90 days ANTX insiders reported 1 open-market buy ($12K) against 9 sells ($318K), so the dollar flow leans toward selling. Latest filing: Marks Gilbert Lynn (Director) on 2026-10-12.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-12 | Marks Gilbert Lynn | Director | Grant | 2K | $0.00 | $0 | 84K |
| 2026-10-12 | Martin Patricia A. | Director | Grant | 389 | $0.00 | $0 | 19K |
| 2026-10-12 | Aziz Kabeer | Director | Grant | 2K | $0.00 | $0 | 62K |
| 2026-09-15 | Trenor Cameron C. III | Chief Medical Officer | Grant | 117K | $0.00 | $0 | 117K |
| 2026-09-09 | Readnour Robin Shane | Director | Sell | 585 | $6.02 | $4K | 625K |
| 2026-09-09 | Readnour Robin Shane | Director | Sell | 523 | $6.02 | $3K | 557K |
| 2026-09-08 | Readnour Robin Shane | Director | Sell | 5K | $6.02 | $32K | 625K |
| 2026-09-08 | Readnour Robin Shane | Director | Sell | 5K | $6.02 | $28K | 558K |
| 2026-09-03 | Readnour Robin Shane | Director | Sell | 3K | $6.07 | $20K | 631K |
| 2026-09-03 | Readnour Robin Shane | Director | Sell | 3K | $6.07 | $17K | 563K |
| 2026-09-01 | Williams Sarah Joanne | Principal Accounting Officer | Sell | 272 | $5.53 | $2K | 66K |
| 2026-09-01 | FitzPatrick Margaret M | Director | Buy | 2K | $5.53 | $12K | 11K |
| 2026-08-17 | Readnour Robin Shane | Director | Sell | 19K | $6.01 | $112K | 634K |
| 2026-08-17 | Readnour Robin Shane | Director | Sell | 17K | $6.01 | $100K | 566K |
| 2026-08-14 | Zakrzewski Joseph S | Director | Gift | 406K | $0.00 | $0 | 0 |
| 2026-07-10 | Aziz Kabeer | Director | Grant | 3K | $0.00 | $0 | 59K |
| 2026-07-10 | Marks Gilbert Lynn | Director | Grant | 3K | $0.00 | $0 | 82K |
| 2026-07-10 | Martin Patricia A. | Director | Grant | 766 | $0.00 | $0 | 19K |
| 2026-07-08 | Eizen Joshua M | See Remarks | Sell | 6K | $4.17 | $25K | 207K |
| 2026-05-29 | Williams Sarah Joanne | Principal Accounting Officer | Sell | 265 | $4.43 | $1K | 67K |
| 2026-04-10 | Aziz Kabeer | Director | Grant | 4K | $0.00 | $0 | 56K |
| 2026-04-10 | Marks Gilbert Lynn | Director | Grant | 4K | $0.00 | $0 | 79K |
| 2026-04-10 | Martin Patricia A. | Director | Grant | 1K | $0.00 | $0 | 18K |
| 2026-03-03 | Williams Sarah Joanne | Principal Accounting Officer | Sell | 327 | $1.06 | $347 | 67K |
| 2026-02-20 | Eizen Joshua M | See Remarks | Grant | 50K | $0.00 | $0 | 207K |
| 2026-02-20 | Day Lucy | Chief Financial Officer | Grant | 38K | $0.00 | $0 | 118K |
| 2026-02-20 | Williams Sarah Joanne | Principal Accounting Officer | Grant | 48K | $0.00 | $0 | 67K |
| 2026-02-20 | Easom Eric | Chief Executive Officer | Grant | 112K | $0.00 | $0 | 369K |
| 2026-02-20 | Chanda Sanjay | Chief Development Officer | Grant | 38K | $0.00 | $0 | 119K |
| 2026-01-12 | Aziz Kabeer | Director | Grant | 12K | $0.00 | $0 | 52K |
| 2026-01-12 | Martin Patricia A. | Director | Grant | 4K | $0.00 | $0 | 17K |
| 2026-01-12 | Marks Gilbert Lynn | Director | Grant | 12K | $0.00 | $0 | 75K |
| 2026-01-06 | Day Lucy | Chief Financial Officer | Sell | 6K | $1.01 | $6K | 75K |
| 2026-01-06 | Prior Stephen David | Chief Strategy Officer | Sell | 3K | $1.01 | $3K | 59K |
| 2026-01-06 | Chanda Sanjay | Chief Development Officer | Sell | 6K | $1.01 | $6K | 76K |
| 2026-01-06 | Eizen Joshua M | See Remarks | Sell | 7K | $1.01 | $7K | 152K |
| 2026-01-05 | Day Lucy | Chief Financial Officer | Sell | 3K | $1.00 | $3K | 81K |
| 2026-01-05 | Prior Stephen David | Chief Strategy Officer | Sell | 4K | $1.00 | $4K | 62K |
| 2026-01-05 | Chanda Sanjay | Chief Development Officer | Sell | 3K | $1.00 | $3K | 82K |
| 2026-01-05 | Eizen Joshua M | See Remarks | Sell | 18K | $1.00 | $18K | 159K |
| 2025-11-04 | Eizen Joshua M | See Remarks | Sell | 3K | $1.14 | $3K | 177K |
| 2025-11-04 | Prior Stephen David | Chief Strategy Officer | Sell | 765 | $1.14 | $872 | 66K |
| 2025-10-10 | Marks Gilbert Lynn | Director | Grant | 10K | $0.00 | $0 | 64K |
| 2025-10-10 | Aziz Kabeer | Director | Grant | 10K | $0.00 | $0 | 41K |
| 2025-10-10 | Martin Patricia A. | Director | Grant | 3K | $0.00 | $0 | 13K |
| 2025-07-10 | Aziz Kabeer | Director | Grant | 12K | $0.00 | $0 | 31K |
| 2025-07-10 | Marks Gilbert Lynn | Director | Grant | 12K | $0.00 | $0 | 53K |
| 2025-07-10 | Martin Patricia A. | Director | Grant | 4K | $0.00 | $0 | 10K |
| 2025-06-02 | Easom Eric | Chief Executive Officer | Buy | 10K | $1.07 | $11K | 256K |
| 2025-05-30 | Leonard Braden Michael | TenPercentOwner | Sell | 425K | $1.01 | $429K | 3.2M |
| 2025-05-30 | Leonard Braden Michael | TenPercentOwner | Sell | 7K | $1.03 | $7K | 3.2M |
| 2025-05-28 | FitzPatrick Margaret M | Director | Buy | 9K | $1.18 | $10K | 9K |
| 2025-05-28 | Leonard Braden Michael | TenPercentOwner | Sell | 2.0M | $1.16 | $2.3M | 3.7M |
| 2025-05-28 | Leonard Braden Michael | TenPercentOwner | Sell | 100K | $1.16 | $116K | 3.6M |
| 2025-05-28 | Leonard Braden Michael | 10% owner | Sell | 200K | $1.09 | $218K | 3.0M |
| 2025-04-10 | Marks Gilbert Lynn | Director | Grant | 10K | $0.00 | $0 | 42K |
| 2025-04-10 | Martin Patricia A. | Director | Grant | 3K | $0.00 | $0 | 6K |
| 2025-04-10 | Aziz Kabeer | Director | Grant | 10K | $0.00 | $0 | 19K |
| 2025-04-10 | Zakrzewski Joseph S | Director | Grant | 11K | $0.00 | $0 | 146K |
| 2025-02-26 | Prior Stephen David | Chief Strategy Officer | Grant | 28K | $0.00 | $0 | 61K |
| 2025-02-26 | Easom Eric | Chief Executive Officer | Grant | 145K | $0.00 | $0 | 246K |
| 2025-02-26 | Eizen Joshua M | See Remarks | Grant | 59K | $0.00 | $0 | 175K |
| 2025-02-26 | Day Lucy | Chief Financial Officer | Grant | 47K | $0.00 | $0 | 79K |
| 2025-02-26 | Chanda Sanjay | Chief Development Officer | Grant | 50K | $0.00 | $0 | 80K |
| 2025-01-03 | Eizen Joshua M | See Remarks | Sell | 10K | $1.34 | $13K | 117K |
| 2025-01-03 | Prior Stephen David | Chief Strategy Officer | Sell | 2K | $1.34 | $3K | 33K |
| 2025-01-03 | Chanda Sanjay | Chief Development Officer | Sell | 3K | $1.34 | $4K | 30K |
| 2025-01-03 | Day Lucy | Chief Financial Officer | Sell | 3K | $1.34 | $4K | 33K |
| 2024-12-19 | Readnour Robin Shane | Director | Grant | 9K | $0.00 | $0 | 9K |
| 2024-12-19 | Zakrzewski Joseph S | Director | Grant | 10K | $0.00 | $0 | 135K |
| 2024-12-19 | Marks Gilbert Lynn | Director | Grant | 9K | $0.00 | $0 | 32K |
| 2024-12-19 | Aziz Kabeer | Director | Grant | 9K | $0.00 | $0 | 9K |
| 2024-12-19 | Martin Patricia A. | Director | Grant | 3K | $0.00 | $0 | 3K |
| 2024-12-10 | Readnour Robin Shane | Director | Buy | 5K | $1.49 | $7K | 582K |
| 2024-12-10 | Readnour Robin Shane | Director | Buy | 5K | $1.49 | $7K | 653K |
| 2024-12-09 | Readnour Robin Shane | Director | Buy | 12K | $1.43 | $18K | 577K |
| 2024-12-09 | Readnour Robin Shane | Director | Buy | 18K | $1.43 | $26K | 648K |
| 2024-12-06 | Readnour Robin Shane | Director | Buy | 13K | $1.45 | $18K | 565K |
| 2024-12-06 | Readnour Robin Shane | Director | Buy | 7K | $1.45 | $9K | 629K |
| 2024-11-27 | Readnour Robin Shane | Director | Buy | 25K | $1.42 | $35K | 552K |
| 2024-11-27 | Zakrzewski Joseph S | Director | Buy | 2K | $1.40 | $3K | 125K |
| 2024-11-27 | Readnour Robin Shane | Director | Buy | 25K | $1.42 | $36K | 623K |
| 2024-11-26 | Readnour Robin Shane | Director | Buy | 13K | $1.39 | $17K | 527K |
| 2024-11-26 | Readnour Robin Shane | Director | Buy | 13K | $1.39 | $17K | 598K |
| 2024-11-20 | Readnour Robin Shane | Director | Buy | 25K | $1.16 | $29K | 585K |
| 2024-11-20 | Readnour Robin Shane | Director | Buy | 25K | $1.15 | $29K | 515K |
| 2024-11-19 | Readnour Robin Shane | Director | Buy | 75K | $1.03 | $78K | 560K |
| 2024-11-19 | Zakrzewski Joseph S | Director | Buy | 5K | $1.01 | $5K | 123K |
| 2024-11-19 | Readnour Robin Shane | Director | Buy | 75K | $1.04 | $78K | 490K |
| 2024-11-18 | Easom Eric | Chief Executive Officer | Buy | 50K | $1.00 | $50K | 1.1M |
| 2024-11-18 | Zakrzewski Joseph S | Director | Buy | 20K | $1.00 | $20K | 118K |
| 2024-11-04 | Eizen Joshua M | See Remarks | Grant | 32K | $0.00 | $0 | 126K |
| 2024-11-04 | Prior Stephen David | Chief Strategy Officer | Grant | 10K | $0.00 | $0 | 35K |
| 2024-08-14 | Leonard Braden Michael | TenPercentOwner | Buy | 1.5M | $1.04 | $1.6M | 5.7M |
| 2024-08-09 | RA Capital Healthcare Fund LP | TenPercentOwner | Sell | 3.4M | $1.08 | $3.7M | 1.7M |
| 2024-08-09 | RA Capital Healthcare Fund LP | TenPercentOwner | Sell | 115K | $1.08 | $124K | 301K |
| 2024-07-10 | Eizen Joshua M | Chief Legal Officer | Grant | 60K | $0.00 | $0 | 95K |
| 2024-03-15 | Easom Eric | Chief Executive Officer | Grant | 99K | $0.00 | $0 | 101K |
| 2024-03-15 | Chanda Sanjay | Chief Development Officer | Grant | 28K | $0.00 | $0 | 28K |
| 2024-03-15 | Krause Kevin Michael | Chief Strategy Officer | Grant | 30K | $0.00 | $0 | 32K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON1 Form 144 notice on file for ANTX worth $6.1M at the prices reported; 1 in the last 90 days worth $6.1M. Latest: Readnour Robin Shane filed on 2026-08-17 to sell 1,012,000 shares ($6.1M) from 2026-08-17.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-17 | Readnour Robin ShaneDirector | 1.0M | $6.1M | 2.682% | 2026-08-17 | Stifel Nicolaus & Company Inc |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON11 holders report 5% or more of ANTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Robert Egen Atkinson at 9.9% of the class (3,697,435 shares), filed 2026-03-16 for an event on 2026-03-09.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-05-15 | 13G/Ano. 1 | Almitas Capital LLCinvestment adviser | 1.5M | 4.1% | 2026-03-31 |
| 2026-03-16 | 13G | Robert Egen Atkinsonindividual, parent holding company | 3.7M | 9.9% | 2026-03-09 |
| 2026-03-16 | 13G | Michael Kramarzparent holding company, individual | 3.7M | 9.9% | 2026-03-09 |
| 2026-03-16 | 13G | Commodore Capital LPinvestment adviser, partnership | 3.7M | 9.9% | 2026-03-09 |
| 2026-03-16 | 13G | Commodore Capital Master LPpartnership | 3.7M | 9.9% | 2026-03-09 |
| 2026-03-13 | 13G | Vivo Opportunity Fund Holdings, L.P.partnership | 2.9M | 8.0% | 2026-03-10 |
| 2026-03-13 | 13G | Vivo Opportunity, LLCother entity | 2.9M | 8.0% | 2026-03-10 |
| 2026-03-13 | 13G | Vivo Opportunity Cayman Fund, L.P.partnership | 289K | 0.8% | 2026-03-10 |
| 2026-03-13 | 13G | Vivo Opportunity Cayman, LLCother entity | 289K | 0.8% | 2026-03-10 |
| 2026-03-13 | 13G | Israel A. Englanderindividual | 2.2M | 6.3% | 2026-03-06 |
| 2026-03-13 | 13G | Millennium Management LLCother entity | 2.2M | 6.3% | 2026-03-06 |
| 2026-03-13 | 13G | Millennium Group Management LLCother entity | 2.2M | 6.3% | 2026-03-06 |
| 2026-03-13 | 13G | Integrated Core Strategies (US) LLCother entity | 2.1M | 6.0% | 2026-03-06 |
| 2026-02-13 | 13G/Ano. 2 | Eric Easomindividual | 2.2M | 7.9% | 2025-12-31 |
13F holders
Tracked managers holding ANTX at their latest 13F. JSON4 of the 30 tracked managers held ANTX at their latest 13F, $16.5M in total at quarter-end prices. Millennium Management is the largest at $11.2M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 2.3M | $11.2M | 0.00% | +96K |
| Citadel Advisors | 2026-06-30 | 952K | $4.6M | 0.00% | +797K |
| Renaissance Technologies | 2026-06-30 | 130K | $628K | 0.00% | -69K |
| Two Sigma Investments | 2026-06-30 | 16K | $77K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
AN2 Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows AN2 Therapeutics (ANTX), SEC CIK 1880438, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-22.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-17.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-05-15.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-12.JSON and CSV
- Company record
- EDGAR filing index for CIK 1880438Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ANTX is sold short?
2,887,692 shares were held short at the 2026-10-15 settlement, 7.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ANTX's daily short volume?
On 2026-11-02, 46,599 of the 110,976 ANTX shares reported to FINRA were sold short, 42.0% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ANTX have fails to deliver?
The SEC's latest file shows 3,427 ANTX shares failed to deliver at settlement 2026-09-22. Fails are reported per settlement date and published twice a month with a lag.
Are ANTX insiders buying or selling?
Over the last 90 days ANTX insiders reported 1 open-market buy ($12K) against 9 sells ($318K), so the dollar flow leans toward selling. Latest filing: Marks Gilbert Lynn (Director) on 2026-10-12.
Have ANTX insiders filed to sell?
1 Form 144 notice on file for ANTX worth $6.1M at the prices reported; 1 in the last 90 days worth $6.1M. Latest: Readnour Robin Shane filed on 2026-08-17 to sell 1,012,000 shares ($6.1M) from 2026-08-17.
Who owns 5% or more of ANTX?
11 holders report 5% or more of ANTX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Robert Egen Atkinson at 9.9% of the class (3,697,435 shares), filed 2026-03-16 for an event on 2026-03-09.
Which tracked 13F managers own ANTX?
4 of the 30 tracked 13F managers held ANTX shares at their latest filing, $16.5M in all. The largest: Izzy Englander's Millennium Management (2.3M shares, $11.2M), Ken Griffin's Citadel Advisors (952K shares, $4.6M), Renaissance Technologies (130K shares, $628K), Two Sigma Investments (16K shares, $77K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.